Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions.

Yang M, O Hara RM Jr, Adair N, Massachi S

Open source

DOI
10.1080/14796694.2026.2728618
Published
2026 Sep 9
Container
Future oncology (London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2728618,
  title = {Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions.},
  author = {Yang M and O Hara RM Jr and Adair N and Massachi S},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2728618},
  url = {https://doi.org/10.1080/14796694.2026.2728618}
}

RIS

TY  - JOUR
TI  - Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions.
AU  - Yang M
AU  - O Hara RM Jr
AU  - Adair N
AU  - Massachi S
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2728618
UR  - https://doi.org/10.1080/14796694.2026.2728618
ER  - 

APA

M, Y., Jr, O. H. R., N, A., & S, M. (2026). Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2728618

Source records